Real-time enrollment status for this relapsed/refractory hematological malignancies clinical trial
Current Status
Recruiting
Checked: August 31, 2026 at 3:50 PM UTC
| NCT Number | NCT07424833 |
| Recruiting Status | Recruiting |
| Condition | Relapsed/Refractory Hematological Malignancies |
| Phase | PHASE1 |
| Target Enrollment | 180 participants |
| Active Locations | 5 sites in the US |
| Sponsor | Ascentage Pharma Group Inc. |
| Last Updated on CT.gov | July 30, 2026 (Jul 30, 2026) |
As of August 31, 2026: Clinical trial NCT07424833 is currently recruiting participants. This phase1 study for relapsed/refractory hematological malignancies is actively seeking new participants at 5 locations across the United States. The study is sponsored by Ascentage Pharma Group Inc.. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT07424833 is actively recruiting participants as of August 31, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 5 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT07424833 was last updated Jul 30, 2026 (July 30, 2026). HelloStudys verifies this status automatically.